Copyright
©2010 Baishideng.
World J Gastroenterol. Feb 14, 2010; 16(6): 770-777
Published online Feb 14, 2010. doi: 10.3748/wjg.v16.i6.770
Published online Feb 14, 2010. doi: 10.3748/wjg.v16.i6.770
Table 2 Design of 6 clinical trials on efficacy of antiviral therapy for HBV-GN
Author | Group | Case (n) | Intervention | Dropped-out (n) | Outcome | Follow-up | ||
CR | VR | Renal insufficiency (n) | ||||||
Lin[16], 1995 | Control | 20 | The same supportive treatment as treatment group | 0 | 7 complete remission, 10 partial remission | 0 HBeAg clearance | UA | 24 mo |
Treatment | 20 | rIFNα, 5 mU (weight < 20 kg), 8 mU (weight ≥ 20 kg), 3 t/w for 12 mo | 0 | 20 complete remission | 16 HBeAg clearance | UA | ||
Bhimma et al[17], 2002 | Control | 20 | Anti-hypertension and diuretics if needed | 0 | 0 complete remission, 5 partial remission | 1 HBeAg clearance | 0 | 40 wk |
Treatment | 24 | rIFNα-2b, 10 mU/m2, 3 t/w for 16 wk | 5 | 10 complete remission, 4 partial remission | 10 HBeAg clearance, 4 reverters, 5 failures | 2 | ||
Lai et al[18], 1991 | Control | 11 | Diuretic agents or dipyridamole or none | 0 | 0 complete remission, 8 partial remission | 0 HBeAg clearance | 4 | 60 mo |
Treatment | 5 | 2 wk of prednisolone 40 mg/d followed by 12 wk of rIFNα-2b 3 mU, 3 t/w | 0 | 1 complete remission, 4 partial remission | 1 HBeAg seroconversion | 1 | ||
Tang et al[19], 2005 | Control | 12 | ACEI or ARB | 0 | 2 complete remission, 2 partial remission | 1 HBeAg clearance, 2 HBeAg seroconversion | 5 ESRD | 49.2 ± 16.5 mo |
Treatment | 10 | 3TC, 100 mg/d, 49.2 ± 16.5 mo, plus ACEI or ARB | 0 | 7 complete remission, 3 partial remission | 8 HBV-DNA clearance (5 HBeAg clearance) | 0 | ||
Panomsak et al[20], 2006 | Control | 10 | ACEI, fish oil, or neither | 3 | 2 complete remission | 0 HBeAg clearance | 2 ESRD | 5-120 mo |
Treatment | 7 | 1 month of prednisolone followed by 3TC in 6 case and IFNα in one case | 0 | 2 complete remission, 5 partial remission | 1 HBeAg seroconversion | 0 | ||
Yang et al[21], 2003 | Control | 14 | The supportive or symptomatic treatment | 0 | 9 complete remission, 2 partial remission | 3 HBeAg seroconversion | 0 | 3.8 ± 2.4 yr |
Treatment | 6 | rIFNα, 1-3 mU, 3 t/w for 3-6 mo | 0 | 3 complete remission, 2 partial remission | 3 HBeAg seroconversion | 0 |
- Citation: Zhang Y, Zhou JH, Yin XL, Wang FY. Treatment of hepatitis B virus-associated glomerulonephritis: A meta-analysis. World J Gastroenterol 2010; 16(6): 770-777
- URL: https://www.wjgnet.com/1007-9327/full/v16/i6/770.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i6.770